Date Filed | Type | Description |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/14/2023 |
8-K
| Quarterly results |
08/10/2023 |
8-K
| Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Departure of Directors or Ce... |
06/28/2023 |
SC 13G/A
| Novo Holdings A/S reports a 4.9% stake in Galera Therapeutics, Inc. |
05/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/11/2023 |
8-K
| Quarterly results |
04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
03/08/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
03/08/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/08/2023 |
8-K
| Quarterly results |
02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
02/09/2023 |
SC 13D
| Blackstone Holdings I/II GP L.L.C. reports a 7.8% stake in Galera Therapeutics, Inc. |
01/25/2023 |
8-K
| Other Events Interactive Data |
12/12/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
12/09/2022 |
8-K
| Quarterly results |
11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/09/2022 |
8-K
| Quarterly results |
10/26/2022 |
8-K
| Quarterly results |
08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/09/2022 |
8-K
| Quarterly results |
06/16/2022 |
8-K
| Quarterly results |
06/10/2022 |
8-K
| Quarterly results |
05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
05/16/2022 |
8-K
| Quarterly results |
04/28/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/28/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/10/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
03/10/2022 |
8-K
| Quarterly results |
02/14/2022 |
SC 13G/A
| CITADEL ADVISORS LLC reports a 0.6% stake in Galera Therapeutics, Inc. |
02/11/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|